Get the latest cancer news and research. Sort by cancer type or read the current headlines to learn what’s happening in the science of cancer detection and treatment, as well as healthy living tips for dealing with cancer.
29
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer. This Phase 3 trial was started based on the results from Phase 2 clinical trials evaluating Nexavar in patients with advanced thyroid cancer.
The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005. Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive.
27
ImmunoCellular Therapeutics, Ltd. (IMUC), a biotechnology company that is focused on the development of novel immune-based cancer therapies, today announced additional data from its Phase I clinical trial evaluating ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).
26
While the nation is debating how best to reform healthcare, the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) announce a new significant tool to improve the quality of care for patients who suffer from brain tumors.
New Mayo Clinic research has found that survival rates of patients with Barrett's esophagus which can be a precursor for esophageal cancer, are no different than the survival rates for the general population. These findings were presented today at the 2009 American College of Gastroenterology Annual Meeting in San Diego.
23
Myriad Pharmaceuticals Inc. today announced the presentation of non-clinical data demonstrating the potent anti-cancer activity of Azixa(TM) (MPC-6827), its small molecule microtubule destabilizing agent, in a model of brain cancer. Azixa is currently in two phase 2 studies for the treatment of primary brain tumors and one phase 2 trial for the treatment of metastatic melanoma.
Biomoda, Inc., a diagnostics company focused on the development of accurate, inexpensive and noninvasive in-vitro tests for the early detection of cancer, has met its recruitment goal for New Mexico veterans with a history of heavy smoking required to complete the Phase II clinical trial of Biomoda's early-stage diagnostic for lung cancer.
22
People who suffer from debilitating neuropathic pain may get more relief and sleep better by combining two commonly-prescribed drugs. A new, federally-funded study by Queen's University researchers has found that taking the drugs together is a more effective treatment than taking either of them individually.
According to a study from the United States, Inhibition of cyclooxygenase-2 (COX-2) pathways may have significant implications for the prevention and treatment of head and neck squamous cell carcinoma (HNSCC). COX-2 is overexpressed in both premalignant lesions and invasive HNSCC.
A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy.
We care about your feedback. Let us know how we can improve your CancerCompass experience.